Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer Clinical Trials in Seoul

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments